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Abstract: 33 
Objective: The objective of this systematic review and meta-analysis was to assess acute 34 
kidney injury (AKI) with combination therapy of vancomycin plus piperacillin-tazobactam 35 
(VAN+PT) in general adult patients and in critically ill adults. Rates of AKI, time to AKI, and odds 36 
of AKI were compared to vancomycin monotherapy (VAN), vancomycin plus cefepime or 37 
carbapenem (VAN+FEP/CAR), or piperacillin-tazobactam monotherapy (PT). 38 
Data Sources: Studies were identified by searching Pubmed, Embase, Web of Science, and 39 
Cochrane from inception to April 2017. Abstracts from selected conference proceedings were 40 
manually searched. 41 
Study selection: Articles not in English, pediatric studies, and case reports were excluded.  42 
Data Extraction: Two authors independently extracted data on study methods, rates of AKI, and 43 
time to AKI. Effect estimates and 95% confidence intervals (CI) were calculated using the 44 
random effects model in RevMan 5.3.  45 
Data synthesis: Literature search identified 15 published studies and 17 conference abstracts 46 
with at least 24,799 patients. The overall incidence of AKI was 16.7%, with 22.2% for VAN+PT 47 
and 12.9% for comparators. This yielded an overall number needed to harm of 11. Time to AKI 48 
was faster for VAN+PT than VAN+FEP/CAR, but not significantly (mean difference -1.30, 49 
95%CI -3.00-0.41 days). The odds of AKI with VAN+PT were increased versus VAN (OR 3.40; 50 
95%CI 2.57-4.50), versus VAN+FEP/CAR (OR 2.68; 95%CI 1.83-3.91) and versus PT (OR 51 
2.70; 95% CI 1.97-3.69). In a small sub-analysis of 968 critically ill patients, the odds of AKI 52 
were increased versus VAN (OR 9.62, 95%CI 4.48-20.68), but not significantly different for 53 
VAN+FEP/CAR (OR 1.43, 95%CI 0.83-2.47) or PT (OR 1.35, 95%CI 0.86-2.11). 54 
Conclusion: The combination of VAN+PT increased the odds of acute kidney injury over VAN, 55 
VAN+FEP/CAR, and PT. Limited data in critically ill patients suggest the odds of AKI are 56 
increased versus VAN, and mitigated versus the other comparators. Further research in the 57 
critically ill population is needed.  58 
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Introduction 59 
Acute kidney injury (AKI) is associated with increased morbidity and mortality (1-4). 60 
There are several definitions, but recent consensus documents focus on three: 1) Risk, Injury, 61 
Failure, Loss, End-stage (RIFLE) (5), 2) Acute Kidney Injury Network (AKIN) (6), and 3) Kidney 62 
Disease: Improving Global Outcomes (KDIGO) (7), which is a combination of the other two 63 
definitions. When defined as an increase in serum creatinine of 0.5mg/dL or greater, one 64 
component of the RIFLE definition, AKI increases length of hospital stay by approximately 3.5 65 
days and costs by ~$7500 (1). Mortality is also increased approximately 6.5-fold, and increases 66 
even more with larger increases in serum creatinine (1). The poor outcomes associated with 67 
AKI have also been demonstrated in several studies of critically ill patients (2, 4, 8, 9), with rates 68 
of AKI in intensive care unit (ICU) populations ranging from 28-67% (8, 10-12).   69 
Historically, risk of AKI during vancomycin treatment has been widely known, and 70 
ranged from 5 to 7% (13, 14). Increases in doses and target trough concentrations may be 71 
responsible for the recent observed increases in rates of vancomycin-associated AKI, up to 72 
43%.(15-19) Although there is some controversy over whether vancomycin monotherapy can 73 
cause nephrotoxicity or AKI in an otherwise healthy person, it is generally agreed that 74 
concomitant nephrotoxic agents, as well as many comorbid conditions and drug exposure 75 
factors, such as dosing, trough concentrations, and duration of therapy, increase this risk (15, 76 
20-22).  Risk factors, including vasoactive medications, hypotension, and increased disease 77 
severity, are often associated with the critically ill population, where vancomycin is prevalent 78 
(23, 24).   79 
Since 2011, there have been multiple studies demonstrating an increase in AKI with 80 
combination therapy of vancomycin plus piperacillin-tazobactam (25-56). Vancomycin plus 81 
piperacillin-tazobactam is one of the most commonly used combinations of antimicrobials with 82 
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widespread use in hospitals (57). Rates of AKI in these initial studies ranged from 18 to 49% 83 
with the combination (32, 33, 49, 52).  Initial reports were small observational studies, often in 84 
very specific patient populations, such as diabetic patients with osteomyelitis or patients in the 85 
surgical ICU.(33, 41, 52)  Given increases in mortality and length of stay associated with AKI 86 
and the widespread use of vancomycin plus piperacillin-tazobactam, this combination could 87 
have a substantial effect on patient outcomes  88 
This systematic review and meta-analysis was performed to determine the association 89 
between vancomycin plus piperacillin-tazobactam and acute kidney injury in adults. . AKI rates 90 
and odds ratios were calculated for each comparator: vancomycin alone, vancomycin plus other 91 
beta-lactams (cefepime or carbapenem), and piperacillin-tazobactam alone. Time to AKI was 92 
evaluated to determine whether onset occurred faster with the combination of vancomycin plus 93 
piperacillin-tazobactam.  Additionally, a sub-analysis in critically ill patients was performed for 94 
each comparator group to determine if the effects were enhanced or mitigated.   95 
  96 
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Methods 97 
Literature Search 98 
Two authors (MKL and TTT) independently performed a systematic literature review. 99 
Pubmed, Embase, Web of Science, and Cochrane were systematically searched from inception 100 
to April 15, 2017. Keywords of vancomycin, piperacillin, and kidney, renal, nephrotoxicity, 101 
nephropathy, nephritis, safety or adverse were used. Reference lists of included studies were 102 
manually searched for relevant studies.    103 
Study Selection 104 
 Titles and abstracts of potentially relevant studies were reviewed. Randomized or 105 
observational reports were eligible to be included in the meta-analysis if they: 1) enrolled adult 106 
patients (≥18 years old), 2) included patients on concomitant vancomycin and piperacillin-107 
tazobactam and either vancomycin alone, vancomycin plus another beta-lactam, or piperacillin-108 
tazobactam alone, and 3) nephrotoxicity/ acute kidney injury rates or odds ratios could be 109 
extracted for each group. All definitions of AKI that referenced specific changes in serum 110 
creatinine (e.g. 1.5-fold or 0.5mg/dL increase), urine output, or need for dialysis/ renal 111 
replacement therapy were included. Studies that used a definition referring to an upper limit of 112 
normal serum creatinine were excluded. Pediatric studies, case reports/ series, and articles not 113 
in English were excluded. Abstracts from conference proceedings were included. In addition to 114 
conference abstracts included in the database search, we manually searched abstract 115 
collections from IDweek, Interscience Conference on Antimicrobial Agents and Chemotherapy 116 
(ICAAC), Kidney Week, American College of Clinical Pharmacy (ACCP), Society of Critical Care 117 
Medicine (SCCM), and American Society of Health-System Pharmacists (ASHP) midyear 118 
meeting for full text abstracts using the keywords vancomycin, piperacillin, or zosyn. Data from 119 
final posters were used when available online. Authors were not contacted for missing data. 120 
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Study Quality 121 
 The quality of included studies was assessed using the Newcastle-Ottawa quality 122 
assessment score (58). Each study was scored from 0 to 9, based on eight criteria covering 123 
selection of cohort, comparability of groups, and outcome. Discrepancies between the two 124 
authors were resolved by consensus.  125 
Data extraction 126 
 Data collected from each study included author, publication year, study design, location 127 
and dates of enrollment, inclusion and exclusion criteria, definition of acute kidney injury used, 128 
medications included, and measures of outcomes (e.g. acute kidney injury rates).  129 
Outcomes 130 
 The primary outcome for the meta-analysis was acute kidney injury, as defined by the 131 
individual study. Most studies used AKIN, RIFLE, KDIGO, or vancomycin consensus guidelines 132 
to define acute kidney injury or nephrotoxicity (5-7, 20). The percentage of patients developing 133 
AKI with each drug regimen were calculated, and used to calculate an overall number needed to 134 
harm. Time to AKI was extracted from studies when provided for groups of interest. Median and 135 
interquartile range were converted to mean and standard deviation using methods from Wan et 136 
al.(59) A secondary analysis was performed for critically ill patients, defined as being in an 137 
intensive care unit, to determine whether the impact of these medications on AKI was mitigated 138 
or enhanced in ICUs.  139 
Statistical Analysis 140 
AKI rate differences, and corresponding p-values, as well as the number needed to harm  141 
were calculated from OpenEpi.(60)  Meta-analysis was performed in Review Manager 5.3 142 
(RevMan; Cochrane Library, UK) (61). Pooled odds ratios (OR) and 95% confidence intervals 143 
7 
 
(CI) were calculated using the generic inverse variance random effects model for each 144 
comparator (vancomycin monotherapy, piperacillin-tazobactam monotherapy, or vancomycin 145 
plus cefepime or a carbapenem). Crude odds ratios were calculated from the raw AKI rates in 146 
each study. Adjusted odds ratios were used over the crude odds ratio when provided for the 147 
groups of interest.  Mean difference in time to AKI was calculated using a random effects model. 148 
Publication bias was assessed using funnel plots. Heterogeneity was assessed by I2 statistic 149 
and Cochran’s Q. A p-value <0.10 was considered statistically significant since Cochran’s Q has 150 
low power. Sensitivity analyses were performed (1) by removing each study individually in order 151 
to determine whether an individual report has higher contribution to the heterogeneity or overall 152 
effect estimate, (2) analyzing published studies separately from abstracts, (3) including only 153 
high quality reports (Newcastle Ottawa score ≥7), and (4) including only reports that used 154 
methods to control for confounding. Reporting for this meta-analysis is in accordance with the 155 
Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) guidance (62). 156 
  157 
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Results 158 
A flow diagram of the literature search is shown in Figure 1. The search identified 15 159 
published studies meeting inclusion and exclusion criteria for the meta-analysis (Supplemental 160 
Table 1). Six studies compared vancomycin plus piperacillin-tazobactam to vancomycin 161 
monotherapy (26, 27, 30, 32, 37, 39), while eight studies compared to vancomycin plus 162 
cefepime or carbapenem (25, 28, 29, 33, 34, 36, 38, 39) and four compared to piperacillin-163 
tazobactam monotherapy (30, 31, 35, 37). Three studies had multiple comparisons (30, 37, 39). 164 
One study was excluded from the vancomycin plus cefepime analysis because the data 165 
overlapped another study (34, 39). We also identified 17 abstracts from conference proceedings 166 
(Supplemental Table 2) (40-56), with a total number of patients from published studies and 167 
conference abstracts of at least 24,799. There is overlap between separate studies from the 168 
same research groups against different comparator antibiotics.(34, 37-39) However, patients in 169 
overlapping groups were not double-counted, so the total number of patients in Supplemental 170 
Tables 1 and 2 is greater than this number.  171 
There were significant differences in study populations evaluated. Mean age ranged 172 
from 48 to 74, and severity of illness differed between studies (29, 30, 36, 52). There were also 173 
differences among the exclusion criteria for studies which included varying serum creatinine 174 
values of >1.2mg/dL(34), >1.5mg/dL(26, 40), >2mg/dL(27), and >2.5mg/dL (36), or creatinine 175 
clearance values of <30(26), <40(33), and <60mL/min(28, 63) (See Supplemental Tables 1 and 176 
2) . Administration of antibiotics was continuous or extended in some patients, but not 177 
others.(41) Comorbidities, such as diabetes, infection type, and other concomitant medications 178 
frequently play a role in AKI, but were not uniform across studies (27, 33). Some studies 179 
controlled for confounding factors in their analyses, by matching patients on other risk factors for 180 
AKI or using logistic regression (27, 32, 34, 44, 53).  Not all studies, however, adjusted for the 181 
same variables.  182 
9 
 
In all reports evaluated, the rate of acute kidney injury ranged from 5 to 65% for 183 
vancomycin plus piperacillin-tazobactam (Figure 2) (27, 29, 33, 46, 51). Overall, 16.7% 184 
developed (4133/24799) acute kidney injury. AKI developed with vancomycin plus piperacillin-185 
tazobactam for 22.2% (2212/9945) of patients, while AKI was reported in 12.9% (1921/14854) 186 
of patients exposed to vancomycin monotherapy, vancomycin plus cefepime or carbapenem, or 187 
piperacillin-tazobactam monotherapy. Using these overall rates of acute kidney injury with 188 
vancomycin plus piperacillin-tazobactam versus comparator antibiotics led to a number needed 189 
to harm of 11. Compared with vancomycin plus piperacillin-tazobactam, AKI rates were 190 
significantly lower in the comparison groups (p<0.00001): 8.1% for vancomycin alone (risk 191 
difference 13.4%, 95% CI 12.2-14.6%), 20.0% for vancomycin plus cefepime of carbapenem 192 
(risk difference 3.8%, 95%CI 2.1-5.5%), and 10.5% for piperacillin-tazobactam alone (risk 193 
difference 10.7%, 95% CI 9.5-11.9%).   194 
Time to AKI, in days, was analyzed (Figure 3). Only studies comparing vancomycin plus 195 
piperacillin-tazobactam to vancomycin plus cefepime reported time to AKI separately for each 196 
group. Among five studies reporting this outcome, time to AKI was shorter with vancomycin plus 197 
piperacillin-tazobactam, but not significantly (mean difference -1.30, 95%CI -3.00-0.41, p=0.14). 198 
Among other studies reporting an average time to AKI for all patients, average AKI onset 199 
occurred by 8 days (27, 28, 32-34, 37, 38, 45, 47, 50). Unfortunately, some studies only 200 
identified AKI within the first 7 days of therapy, or excluded patients with AKI within 48-72h 201 
depending on the study’s inclusion criteria for minimum antibiotic duration (26, 50, 51). 202 
Vancomycin plus piperacillin-tazobactam increased the odds of AKI versus each 203 
comparator. The odds of AKI increased with vancomycin plus piperacillin-tazobactam versus 204 
vancomycin monotherapy (OR 3.40, 95%CI 2.57-4.50; Figure 4A). Compared to vancomycin 205 
plus cefepime or carbapenem, the OR for AKI with vancomycin plus piperacillin-tazobactam was 206 
2.68 (95%CI 1.83-3.91; Figure 4B), and compared to piperacillin-tazobactam monotherapy, the 207 
OR was 2.70 (95% CI 1.97-3.69; Figure 4C). Heterogeneity was significant for each of these 208 
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analyses (I2 ≥ 53%, p≤0.01). In an analysis separating studies with vancomycin plus cefepime 209 
and vancomycin plus carbapenem, no significant differences in the OR for AKI were found (2.39 210 
vs 3.46, respectively, p=0.33, see Supplemental material).  211 
Among critically ill populations, the odds of AKI vary depending on the comparator 212 
antibiotic. One recent study of the critically ill found no significant increase in AKI with the 213 
combination of vancomycin and piperacillin-tazobactam compared to vancomycin plus cefepime 214 
(29). Another study found an almost 10-fold increase compared to vancomycin monotherapy in 215 
patients from a surgical ICU (52). Two studies in patients in burn units also found 7 to 10-fold 216 
increases in AKI over vancomycin monotherapy (46, 54). The meta-analysis of critically ill 217 
patients included three studies comparing to vancomycin alone, three studies comparing to 218 
vancomycin plus cefepime or carbapenem, and one study comparing to piperacillin-tazobactam 219 
alone, for a total of 968 patients. In the subset of critically ill patients, the odds of AKI compared 220 
to vancomycin were increased (OR 9.62; 95%CI 4.48-20.68; Figure 5). The odds of AKI 221 
compared to vancomycin plus cefepime or carbapenem, or piperacillin-tazobactam alone were 222 
decreased and no longer significantly different.  223 
Multiple sensitivity analyses were conducted, which resulted in overall similar odds 224 
ratios. In a sensitivity analysis evaluating the removal of individual studies, only Rutter et al. 225 
comparing vancomycin plus piperacillin-tazobactam to vancomycin alone resulted in significant 226 
changes in the heterogeneity, which accounted for over 2/3rds of patients in this analysis, with a 227 
relatively small confidence interval.(37) In a sensitivity analyses looking at published studies 228 
versus abstracts, the ORs for published manuscripts were similar to the overall analysis 229 
(published and abstracts) for vancomycin monotherapy and vancomycin plus cefepime or 230 
carbapenem, but the heterogeneity was lower for published studies (p>0.10; see Supplemental 231 
material). The point estimate for published manuscripts was slightly lower for piperacillin-232 
tazobactam (1.89 vs 2.70), but heterogeneity was still significant (I2=59%, p=0.06). In the quality 233 
assessment, the range of NOS scores was between 3 and 9 (maximum of 9; see supplemental 234 
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Table 3). Sensitivity analyses using only high quality reports with a NOS≥7 and one with reports 235 
that utilized methods to control for confounding, demonstrated similar odds ratios to the primary 236 
analysis which included all reports (see supplemental material). Of note, all high quality reports 237 
used methods to control confounding. In these analyses, only two studies compared 238 
vancomycin plus piperacillin-tazobactam to piperacillin-tazobactam monotherapy. Between-239 
study heterogeneity remained significant.    240 
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Discussion 241 
 This systematic review and meta-analysis demonstrated increased odds of acute kidney 242 
injury with concomitant vancomycin and piperacillin-tazobactam use. This increase was 243 
observed with multiple comparison groups, including vancomycin monotherapy, vancomycin 244 
plus cefepime or a carbapenem, and piperacillin-tazobactam monotherapy.  245 
The results of this meta-analysis are overall similar to another meta-analysis published 246 
on vancomycin and piperacillin-tazobactam, which demonstrated aORs of 2.50 (95%CI 0.41-247 
15.44) for vancomycin alone, 3.78 (95%CI 2.48-5.78) for vancomycin plus cefepime, and 3.15 248 
(95%CI 1.72-5.76) for adults (63).  A second, recent meta-analysis also demonstrated OR of 249 
3.65 (95%CI 2.16-6.17) for vancomycin plus beta-lactam and 3.98 (95%CI 2.75-5.76) for 250 
vancomycin alone (64). Of note, the other meta-analyses on this topic have included pediatric 251 
studies. This is the first meta-analysis, to our knowledge, to calculate a number needed to harm 252 
for AKI with vancomycin plus piperacillin-tazobactam therapy. It also includes a sub-analysis of 253 
only critically ill patients, which have not been documented in previous meta-analyses.  254 
Hammond et al. included an analysis by percentage of patients in ICUs (63). This analysis 255 
demonstrated non-significant results for studies with more than 50% ICU patients with an aOR 256 
of 2.83 (95%CI 0.74-10.85) using four studies, mostly in children.  257 
Among the critically ill adult population, there was wide variability in the odds of AKI, 258 
depending on the comparator medication (Figure 5). Within each comparator group, however, 259 
there was no heterogeneity observed. The meta-analysis subgroup of critically ill patients is 260 
relatively small, since not all studies included data specifically on ICU patients, but was able to 261 
demonstrate statistically significant results for vancomycin plus piperacillin-tazobactam versus 262 
vancomycin monotherapy (OR 9.62; 95% CI 4.48-20.68). Only seven studies included critically 263 
ill data, with a total of 968 patients. None of these studies included adjusted odds ratios for 264 
these patients, so it is possible that risk factors for kidney injury, such as severity or type of 265 
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illness, contrast media, hypotension, or other factors are responsible or playing a role in these 266 
cases of AKI.  Randomized controlled trials comparing monotherapy and combination therapy 267 
are unlikely, but by comparing vancomycin plus piperacillin-tazobactam to vancomycin plus 268 
cefepime or carbapenem, some of the concerns about confounding can be limited. These 269 
patients would theoretically have similar risks of sepsis or ICU admission, however this may not 270 
eliminate potential confounding entirely. The critically ill subset of this meta-analysis with 271 
vancomycin plus cefepime or carbapenem did not demonstrate significant differences in AKI 272 
from vancomycin plus piperacillin-tazobactam (OR 1.43; 95% CI 0.83-2.47) which may indicate 273 
that these patients are similar, or have more similar risks for AKI. Only one study in the literature 274 
search included data on AKI in critically ill patients on piperacillin-tazobactam monotherapy, in 275 
patients with intraabdominal infections (35). This study was included as a comparator in the 276 
critically ill sub-analysis, but should be considered carefully due to the limited size and lack of 277 
similar studies in the meta-analysis. The analysis demonstrates possible differential effects in 278 
ICU patients, which should be investigated in future studies. In addition, prospective randomized 279 
controlled trials investigating vancomycin plus piperacillin-tazobactam versus vancomycin plus 280 
cefepime would be helpful in determining the true effect size.   281 
It may be of clinical interest to compare the vancomycin plus cefepime and vancomycin 282 
plus carbapenem subgroups. In these analyses, there was no significant difference in the odds 283 
of AKI versus vancomycin plus piperacillin-tazobactam. One study included both cefepime and 284 
carbapenem, with a wide confidence interval (1.54-33.15) (36), but the chi-square test remained 285 
non-significant when removed, indicating no difference between the cefepime and carbapenem 286 
subgroups. There were, however, only three studies, and a limited number of patients, that used 287 
vancomycin plus carbapenem (see Supplemental material).  Consideration may be given to 288 
clinical scenarios or select patients in which vancomycin plus cefepime or a carbapenem may 289 
be preferable for antibiotic coverage to limit the risk of AKI. 290 
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 Given the number needed to harm of 11, along with the widespread use of this 291 
combination therapy, AKI with vancomycin plus piperacillin-tazobactam likely has a large impact 292 
on patient outcomes with the increased length of stay, costs, and mortality associated with AKI 293 
(1). Although AKI with vancomycin is typically reversible, even transient AKI in critically ill 294 
patients has been associated with increased mortality (8). Daily ICU costs can also be much 295 
higher, which would increase the costs above the $7500 previously quoted for hospital-wide 296 
patients (1). Reducing the use and duration of vancomycin and piperacillin-tazobactam could 297 
reduce AKI incidence (31, 34). Strategies to aid in this aim include utilizing antimicrobial 298 
stewardship policies; such as protocols for using alternative antibiotics when appropriate, 299 
institution-specific guidance on when combination therapy is necessary, and institutional 300 
antibiograms for susceptibility. Other stewardship programs have utilized antibiotic restriction 301 
and time-outs to decrease use of vancomycin and/or piperacillin-tazobactam (31, 65). 302 
Stewardship programs have thus demonstrated reduced rates of AKI (27). Most studies in the 303 
meta-analysis required at least 48-72h of antibiotic therapy to be included, and the analysis of 304 
time to AKI noted an onset within 8 days. Rapid diagnostic test implementation in hospital 305 
settings may help to de-escalate from vancomycin plus piperacillin-tazobactam therapy sooner, 306 
potentially avoiding AKI.(66)  Unfortunately, time to AKI was not available for studies in ICU 307 
populations, so further research is needed. 308 
The mechanism of increased AKI with vancomycin and piperacillin-tazobactam is not 309 
known. Though there are reports of acute kidney injury or acute interstitial nephritis with 310 
cefepime, carbapenems, and other non-piperacillin-tazobactam beta-lactams, these reports are 311 
rare compared to the studies of piperacillin-tazobactam (67-69). One study also noted that 312 
piperacillin-tazobactam had the lowest renal recovery rate (measured by change in creatinine 313 
clearance) among beta-lactams tested, indicating possible kidney hazard with piperacillin-314 
tazobactam (70). Piperacillin-tazobactam has not traditionally been considered a nephrotoxic 315 
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medication, however several studies, and the pooled percentages of AKI we calculated, 316 
demonstrated increased odds of AKI with piperacillin-tazobactam monotherapy over 317 
vancomycin monotherapy (30, 41, 42, 44, 49, 55). Since both vancomycin and piperacillin-318 
tazobactam have been associated with interstitial nephritis, and vancomycin has also been 319 
associated with acute tubular necrosis, it is possible that this combination has augmented 320 
effects on nephrotoxicity rates (71-73). Recent studies have also identified compatibility issues 321 
with different concentrations of vancomycin and piperacillin-tazobactam (74-78). Although it is 322 
not clear from these studies what happens in the bloodstream, precipitation of these 323 
medications could lead to kidney damage.  324 
There are other limitations to this analysis. These observational studies are subject to 325 
possible bias such as confounding by indication, since patients receiving different therapies are 326 
likely different in other ways. There is also the possibility of misclassification bias; it is not clear 327 
in all the studies whether the vancomycin alone group received other antibiotics (ie, not 328 
piperacillin-tazobactam) that may include cefepime or carbapenems. The results, however, of 329 
the meta-analyses for vancomycin alone and vancomycin plus cefepime or carbapenem were 330 
similar, and any changes from misclassification would likely be small. We cannot rule out 331 
publication bias among the included reports (supplemental material). Larger studies and studies 332 
indicating a higher risk of AKI with combinations of vancomycin and piperacillin-tazobactam may 333 
be more likely to be published than those not demonstrating a significant difference. In the 334 
funnel plots in supplemental material, this is indicated by the lack of studies with low ORs and 335 
higher standard errors. We chose to present the results of conference abstracts, to see the 336 
impact on the overall odds ratio and compare the results. Of course, conference abstracts have 337 
limitations, including that they may have been edited before final presentation, they are not 338 
always peer-reviewed, and some information may be missing. Additionally, not all abstracts 339 
from the included conferences could be accessed in the collections searched. Our results, 340 
16 
 
including abstracts from well-known infectious diseases, critical care, and pharmacy 341 
conferences, however, indicated similar odds of AKI as published studies.  342 
17 
 
Conclusion 343 
Available literature suggests that the combination of vancomycin plus piperacillin-344 
tazobactam increases the odds of acute kidney injury approximately 3-fold. This increased risk 345 
was present versus vancomycin monotherapy, piperacillin-tazobactam monotherapy, and 346 
vancomycin plus cefepime or carbapenem combination therapy. Although small, the analysis of 347 
critically ill patients suggests the odds of AKI with vancomycin plus piperacillin-tazobactam are 348 
increased over vancomycin monotherapy, but mitigated versus vancomycin plus cefepime or 349 
carbapenem. Further research in critically ill patients is needed. 350 
 351 
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Figure 1. Literature search flow diagram. 360 
Abbreviations:  ICAAC, Interscience Conference on Antimicrobial Agents and Chemotherapy; 361 
ACCP, American College of Clinical Pharmacy; SCCM, Society of Critical Care Medicine; 362 
ASHP, American Society of Health-System Pharmacists 363 
 364 
 365 
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Figure 2. Scatterplot of percentage of patients with acute kidney injury in included studies. 368 
 369 
Abbreviations: VAN+PT, vancomycin plus piperacillin-tazobactam; VAN, vancomycin; 370 
FEP/CAR, cefepime or carbapenem; PT, piperacillin-tazobactam; AKI, acute kidney injury. 371 
 372 
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Figure 3. Mean difference in time (days) to acute kidney injury for vancomycin plus piperacillin-374 
tazobactam versus vancomycin plus cefepime.  375 
  376 
Abbreviations: VAN+PT, vancomycin plus piperacillin-tazobactam; FEP, cefepime; IV, inverse 377 
variance; SD, standard deviation; CI, confidence interval. 378 
 379 
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Figure 4. Forest Plot demonstrating the odds of acute kidney injury with vancomycin plus 381 
piperacillin-tazobactam versus A) vancomycin monotherapy B) vancomycin plus cefepime or a 382 
carbapenem C) piperacillin-tazobactam monotherapy. 383 
*Indicates adjusted odds ratio.  384 
Abbreviations: VAN+PT, vancomycin plus piperacillin-tazobactam; VAN, vancomycin 385 
monotherapy; FEP/CAR, cefepime or a carbapenem; PT, piperacillin-tazobactam monotherapy; 386 
SE, standard error; IV, inverse variance; CI, confidence interval; AKI, acute kidney injury 387 
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Figure 5. Forest Plot demonstrating the odds of acute kidney injury in critically ill patients.  389 
Abbreviations: VAN+PT, vancomycin plus piperacillin-tazobactam; VAN, vancomycin 390 
monotherapy; FEP/CAR, cefepime or a carbapenem; PT, piperacillin-tazobactam monotherapy; 391 
SE, standard error; IV, inverse variance; CI, confidence interval; AKI, acute kidney injury 392 
 393 
 394 
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